Two-Pronged immune attack tested against standard care in advanced stomach cancer fight
NCT ID NCT06346197
Summary
This study is testing whether a new combination of two immunotherapy drugs (botensilimab + balstilimab) works better than the current standard treatment for people with advanced stomach, esophageal, or gastro-esophageal junction cancers that have specific genetic features (MSI-H/dMMR). The trial will enroll 132 adults who have not yet received treatment for their advanced cancer. Participants will be randomly assigned to receive either the new two-drug immunotherapy or the standard treatment, which combines chemotherapy with a different immunotherapy drug (nivolumab).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Brest
RECRUITINGBrest, 29000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Poitiers
RECRUITINGPoitiers, 86000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Léon Bérard
RECRUITINGLyon, 69008, France
Contact Email: •••••@•••••
-
Hôpital Privé Jean Mermoz
RECRUITINGLyon, 69008, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Paoli Calmettes
RECRUITINGMarseille, 13000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.